Professor Dr. Dirk Jäger

Managing Director, NCT Heidelberg
Responsible for the entire clinical area at the National Center for Tumor Diseases (NCT) Heidelberg
Medical Director:
Medical Oncology

Phone:  +49 6221 56-7229
Fax:  +49 6221 56-7225
E-mail: dirk.jaeger@med.uni-heidelberg.de

Since July 1, 2005 Professor Dirk Jäger has been heading the Department of Medical Oncology at the NCT Heidelberg and he is responsible for the entire clinical area at the NCT.
All oncological units at the University Hospital are integrated into the interdisciplinary outpatients' structure at the NCT. An important focus is translation of innovative therapeutic approaches into early clinical trials. The strategies that use the human immune system for the treatment of tumors play an important part.

since 01.07.2005
Chair, Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital

since 2013
Head of a research unit at DKFZ: Applied Tumor Immunity

2003
2005
Attending physician (Leitender Arzt) at the Department of Oncology, University Hospital Zurich (A. Knuth)

2000–2003
Attending physician at the Department of Hematology/Oncology, Krankenhaus Nordwest, Frankfurt (A. Knuth)

2003
Specialty in Hematology/Oncology

2003
Habilitation in Internal Medicine, Johannes Gutenberg University Mainz

1998–2000

Research fellowship at the Department of Pathology, Cornell Medical Center, New York, and the Ludwig Institute, New York Branch (L.J. Old, Y.T. Chen), funded by the Cancer Research Institute, New York
Topic: `Identification and characterization of novel tumor antigens in breast cancer and melanoma´

1998
Specialty in Internal Medicine

1995–1998
Attending physician at the Department of Hematology/Oncology, Krankenhaus Nordwest, Frankfurt (A. Knuth)

1993 - 1995
Resident at the Department of Internal Medicine
St. Josefs Hospital, Berlin (Prof. Dr. T. Poralla)

1992 - 1993
Resident at the Department of Internal Medicine, Gastroenterology, Oncology at the University Hospital Regensburg (J. Schölmerich)

Since 2007
Official Affiliation with the Ludwig Institute for Cancer Research (LICR)

2006
Investigator Award, Cancer Research Institute, New York

Since 2006
Member of the Cancer Vaccine Collaborative, Cancer Research Institutes, New York

Since 2005
Head of the Tumor Immunology Program at NCT
Head of the Immunotherapy Program at NCT
Head of the Clinical Research Program at NCT

2003-2005
PI of the Laboratory for Tumor Immunology at the Oncology Department, University Hospital Zurich

2001- 2003
PI of the Research Group '"Tumor antigen identification and characterization" at the Department of Hematology/Oncology, Krankenhaus Nordwest, Frankfurt

1998 – 2000
Research fellowship of the Cancer Research Institute, New York at the Department of Pathology, Cornell Medical Center, New York, and the Ludwig Institute, New York Branch (L.J. Old, Y.T. Chen), "Identification and characterization of novel target antigens in breast cancer and melanoma"

1991
Doctoral thesis: "Das Phänomen der Translokation von Bakterien und Bakterienprodukten nach Koloskopien" (The phenomenon of bacterial translocation following colonoscopy), Albert-Ludwigs-University Freiburg, Head: Prof. Dr. med. E. A. Farthmann

1991
III. Medical preliminary examination ("III. Ärztliche Prüfung"), Albert-Ludwigs-University Freiburg

1985 - 1987   
Pre-clinic ("Vorklinik") and medical preliminary examination ("Ärztliche Vorprüfung"), Medical University Lübeck

1987 - 1988
Clinical studies and I. medical preliminary examination ("I. Ärztliche Prüfung"), Medical University Lübeck

1988 - 1990
Clinical studies and II. medical preliminary examination ("II. Ärztliche Prüfung"), Albert-Ludwigs-University Freiburg

1990 - 1991
Final year training ("Praktisches Jahr"), Karlsruhe Municipal Hospital ("Städtisches Klinikum"), Karlsruhe

1985 - 1991    
Medical studies, Lübeck and Freiburg

1970 - 1983    
Carlo Mierendorff Schule and Rabanus Maurus Gymnasium, Mainz

Birgit Eberle

Secretariat, Medical Oncology
Phone: +49 6221 56-7229
Fax: +496221 56-7225
birgit.eberle@nct-heidelberg.de

Secretariat, Medical Oncology
Phone: +49 6221 56-7229
Fax: +49 6221 56-7225
silke.hirsch@nct-heidelberg.de

Kirsten Bikowski

Executive assistant
Phone: +49 6221 56-6904
Fax: +49 6221 56-7225
kirsten.bikowski@nct-heidelberg.de

Dr. Paula Klug

Executive assistant
Phone: + 49 6221 56-38016
Fax: + 49 6221 56-7225
paula.klug@nct-heidelberg.de

Dr. Reinhard Liebers

Scientific Coordinator
Phone: +49 6221 56-34609
Fax: +49 6221 56-7225
reinhard.liebers@nct-heidelberg.de

  1. Tumoral immune cell exploitation in colorectal cancer liver metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jäger D. Cancer Cell 2016, 29(4):587-601.
  2. Prognostic Significance of Spontaneous Antibody Responses against Tumor-Associated Antigens in Malignant Melanoma Patients. Zörnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk CS, Eichmueller SB, Jäger D. Int J Cancer 2015, 136:138-51.
  3. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Cell Res.  2015, 25(2):208-24.
  4. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Krawczyk A, Arndt MA, Grosse-Hovest L, Weichert W, Giebel B, Dittmer U, Hengel H, Jäger D,  Schneweis KE, Eis-Hübinger AM, Roggendorf M, Krauss J.  Proc Natl Acad Sci USA 2013, 110(17):6760-5.
  5. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schäkel K, Garbi N, Jäger D, Weitz J, Schmitz-Winnenthal H, Hämmerling GJ, Beckhove P. Cancer Cell 2013, 24(5):589-602.
Professor Dr. Dirk Jäger